相关实验视频

Updated: Jun 21, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

降脂药与肠道微生物群的关联:孟德尔的随机化研究

Lubo Shi¹, Xiaoduo Liu², Enze Li³

¹Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing Digestive Disease Center, Beijing, PR China (Drs Shi, Zhang, Zhou).

Journal of clinical lipidology

|July 6, 2024

概括

降脂药物,包括PCSK9,NPC1L1和HMGCR抑制剂,影响肠道微生物群的组成. 这项门德尔随机化研究揭示了与细菌属和序列的变化相关的特定药物标.

科学领域:

遗传学是一个遗传学.
微生物学微生物学
药理学药理学是指药理学的学科.

背景情况:

脂质代谢显著影响肠道微生物群.
降脂药物对于管理心血管健康至关重要.
了解药物与微生物群的相互作用对于个性化医学至关重要.

研究的目的:

研究降脂药物对肠道微生物群组成的因果影响.
为了区分PCSK9,NPC1L1和HMGCR抑制剂对特定肠道细菌的影响.
使用门德尔的随机化 (MR) 来评估药物点与微生物群的关系.

主要方法:

在药物标基因附近使用遗传变异作为降脂药物暴露的工具变量.
利用全基因组关联研究 (GWAS) 的低密度脂蛋白胆固醇 (LDL-C) 数据.
应用逆方差加权MR (IVW-MR) 和基于总结数据的MR (SMR) 与灵敏度分析.

主要成果:

降脂药物的遗传代理物对肠道微生物群的丰富性表现出广泛的影响.
尼曼-皮克C1-Like 1蛋白 (NPC1L1) 的抑制与埃格特拉菌的增加有关.
3-基-3-甲基氨基-CoA减少酶 (HMGCR) 抑制影响了巴斯图雷拉类和血友类.
蛋白转化酶亚提利辛/素9型 (PCSK9) 抑制与Terrisporobacter的增加有关.
没有检测到性质的证据,支持发现的有效性.

结论:

药物目标门德尔随机化强调了降脂药物对肠道微生物群的干预潜力.
不同类型的降脂药对特定的肠道微生物群落产生不同的作用.
这些发现为探索与脂质管理结合的微生物向治疗提供了基础.

关键词:

因果关系是因果关系.我们的肠道微生物群.降脂药物降脂药物降脂药物门德尔的随机化

更多相关视频

Murine Fecal Isolation and Microbiota Transplantation

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Factors Influencing Drug Absorption: Disease States and Pharmacology

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...